WO2021137398A1 - Milieu conditionné comprenant une concentration élevée de vésicules extracellulaires liées à la lactoferrine - Google Patents

Milieu conditionné comprenant une concentration élevée de vésicules extracellulaires liées à la lactoferrine Download PDF

Info

Publication number
WO2021137398A1
WO2021137398A1 PCT/KR2020/014092 KR2020014092W WO2021137398A1 WO 2021137398 A1 WO2021137398 A1 WO 2021137398A1 KR 2020014092 W KR2020014092 W KR 2020014092W WO 2021137398 A1 WO2021137398 A1 WO 2021137398A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture medium
lactoferrin
extracellular vesicles
conditioned
skin
Prior art date
Application number
PCT/KR2020/014092
Other languages
English (en)
Korean (ko)
Inventor
김준호
유가은
이정선
장송선
Original Assignee
주식회사 바이오솔루션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 바이오솔루션 filed Critical 주식회사 바이오솔루션
Publication of WO2021137398A1 publication Critical patent/WO2021137398A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Definitions

  • the present invention relates to a conditioned medium containing a high concentration of extracellular vesicles binding to lactoferrin obtained by culturing cells in a culture medium containing lactoferrin.
  • the present invention also relates to a cosmetic composition and a pharmaceutical composition comprising the conditioned culture solution.
  • the skin consists of three layers: the epidermis, the dermis, and the subcutis, and the layer deeply related to skin aging and regeneration is the dermis.
  • Dermal fibroblasts present in the dermal layer maintain the structure of the dermal layer or produce collagen, Fibronectin, and elastin, which are major factors of the extracellular matrix that give elasticity. It synthesizes or produces proteins such as TIMP (Tissue Inhibitor of Metalloproteinase) that help it.
  • TIMP tissue Inhibitor of Metalloproteinase
  • damage to fibroblasts reduces the extracellular matrix or generates a matrix metalloproteinase (MMP) that breaks down cross links.
  • MMP matrix metalloproteinase
  • Extracellular vesicles have recently been in the spotlight.
  • Extracellular vesicles are vesicles having a phospholipid bilayer structure with a size of 30 nm to 1 ⁇ m that originates from the cell and is discharged out of the cell.
  • Extracellular vesicles are composed of exosomes and microvesicles, and the two pathways are different. Exosomes are generated in various sizes in multivesicular endosomes and then released out of the cell, and microvesicles are released as the plasma membrane of the cell forms an endoplasmic reticulum directly outside the cell.
  • the efficacy of the extracellular vesicles on skin regeneration or hair growth has been consistently presented (J Extracell Vesicles. 2019 Jan 20;8(1):1565885, Sci Rep. 2017 Nov 14;7(1):15560).
  • the conventional cell culture medium has a low ratio of extracellular vesicles, there has been a problem in terms of mass production or cost of extracellular vesicles.
  • the present inventors confirmed that, through previous studies, when cells were cultured by adding a lactoferrin/calcium composition to the culture medium, the intracellular calcium concentration increased and the amount of extracellular vesicles excreted thereby increased significantly. However, the efficacy or effect of the conditioned culture medium obtained by the above method has not been specifically confirmed to date.
  • lactoferrin increases the production signal of extracellular vesicles
  • lactoferrin receptor called GAPDH present on the surface of extracellular vesicles and be released together with the extracellular vesicles.
  • lactoferrin would enhance the skin regeneration effect of extracellular vesicles by improving the binding capacity of extracellular vesicles with skin cells by increasing the number of extracellular vesicles in the culture medium as well as decreasing the negative charge of the extracellular vesicles.
  • an object of the present invention is to provide a conditioned culture medium that increases the content of extracellular vesicles and enhances the skin regeneration efficacy of extracellular vesicles.
  • lactoferrin binds to the extracellular vesicles and reduces the strong membrane negative charge of the extracellular vesicles, thereby improving the binding ability of the extracellular vesicles with the skin cells. It was found to enhance the skin regeneration effect.
  • a conditioned culture medium containing a high concentration of extracellular vesicles binding to lactoferrin obtained by culturing cells in a culture medium containing lactoferrin can enhance skin regeneration and skin barrier, and completed the present invention. did it
  • the conditioned culture medium containing a high concentration of extracellular vesicles bound to lactoferrin of the present invention has a positive effect of increasing skin regeneration efficacy due to the significantly higher number of extracellular vesicles in the culture medium, and the positive charge of lactoferrin reduces the negative charge of extracellular vesicles This has the advantage of maximizing the skin regeneration effect by increasing the binding ability of the extracellular vesicles with the skin cells, thereby increasing the skin regeneration effect synergistically.
  • the conditioned culture medium containing a high concentration of extracellular vesicles bound to lactoferrin of the present invention increases the factors responsible for the skin barrier and moisturizing role, thereby showing the effect of restoring the damaged skin barrier.
  • the conditioned culture medium of the present invention can be used as a raw material for cosmetics and pharmaceuticals for skin regeneration strengthening and skin barrier strengthening.
  • 1 is a result of measuring the number of extracellular vesicles generated by a serum substitute alone and a serum substitute/lactoferrin/calcium combination with a nanoparticle tracking analyzer.
  • Figure 2 is the result of measuring the size of the extracellular vesicles generated by the combination of serum replacement agent alone and serum replacement agent/lactoferrin/calcium with a nanoparticle tracking analyzer.
  • 3 is a result of observing the shape of extracellular vesicles generated by using a serum substitute alone and a serum substitute/lactoferrin/calcium combination through a transmission electron microscope.
  • 5 is a graph quantifying the amount of lactoferrin bound to the extracellular vesicles produced by the combination of serum substitute alone and serum substitute/lactoferrin/calcium by ELISA.
  • FIG. 6 is a result of measuring the membrane charge of extracellular vesicles generated by a serum substitute alone and a serum substitute/lactoferrin/calcium combination using a zeta potential & particle size analyzer.
  • FIG. 9 is an RT-PCR result showing the change in the expression of extracellular matrix in fibroblasts by a culture medium cultured with a serum substitute alone and a serum substitute/lactoferrin/calcium combination.
  • 11 is a result of an MTT assay confirming the proliferation rate of fibroblasts by comparing the number of extracellular vesicles generated by the combination of serum substitute alone and serum substitute/lactoferrin/calcium.
  • MMP extracellular matrix and metalloprotease
  • the present invention relates to a conditioned medium containing a high concentration of extracellular vesicles binding to lactoferrin obtained by culturing cells in a culture medium containing lactoferrin.
  • the binding of extracellular vesicles to lactoferrin can enhance the binding of extracellular vesicles to cells.
  • extracellular vesicles in a culture medium obtained by culturing cells in a culture medium to which lactoferrin is added have a lactoferrin receptor, and thus have a possibility of binding lactoferrin to extracellular vesicles. This binding reduces the negative charge of the extracellular vesicle and induces a phenomenon that maximizes the binding between the extracellular vesicle and the cell.
  • culture medium refers to the medium before culturing the cells
  • culture medium or conditioned medium refers to the medium obtained after culturing the cells.
  • extracellular vesicles includes all of the nano-sized (30 ⁇ 2,000 nm) vesicles released to the outside of the cell composed of a phospholipid bilayer, which is the same component as the structure of the cell membrane. Thus, it encompasses “Exosome” and “Microvesicle” that are released from the cell. Furthermore, the term “extracellular vesicle” is meant to encompass Ectosome, Microparticle, Tolerosomes, Prostatosomes, Cardiosomes and Vexosomes. is also used as
  • the number of extracellular vesicles in the conditioned culture medium of the present invention may be in the range of 1.0 ⁇ 10 8 /ml to 1.0 ⁇ 10 11 /ml, specifically 1.0 ⁇ 10 9 /ml to 1.0 ⁇ 10 11 /ml may be in the range.
  • the conditioned culture medium of the present invention may contain lactoferrin at a concentration of 0.1 ⁇ g/ml to 1 mg/ml in the culture medium before culturing, and 0.01 ⁇ g/ml to 1 mg/ml of lactoferrin in the conditioned culture medium after culturing may be present at a concentration of
  • the lactoferrin in the conditioned culture medium of the present invention may be selected from the group consisting of Holo-lactoferrin, Apo-lactoferrin and Pis-lactoferrin.
  • the lactoferrin may be synthesized or obtained by extraction, and includes both human and non-human animals.
  • calcium may be additionally added to the culture medium prior to culture in the conditioned culture medium of the present invention.
  • the calcium may be added to the culture medium before culturing at a concentration of 0.2 ⁇ M to 10 mM, and calcium in the conditioned culture medium after culture may be present at a concentration of 0.02 ⁇ M to 10 mM.
  • the calcium may be added in the form of calcium ions (Ca 2+ ), and the source of the calcium ions includes all salts capable of supplying calcium ions.
  • one or more substances selected from the group consisting of basal media, serum replacement and serum may be additionally added to the culture medium before culture.
  • the "serum substitute" refers to a single substance or a composition substance that replaces serum for preparing a serum-free medium.
  • the cells used in the preparation of the conditioned culture medium of the present invention may be all types of cells derived from humans or animals.
  • the cell is a cell having the ability to regenerate the skin, specifically, the cell having the ability to regenerate the skin may be a stem cell, but is not necessarily limited to a stem cell.
  • stem cell a cell having the ability to regenerate the skin
  • human adipose-derived mesenchymal stem cells were used as the cells, but the present invention is not limited thereto.
  • mesenchymal stem cells for example, adipose (Adipose), umbilical cord (Umbilical cord), umbilical cord blood (Umbilical cord blood), bone marrow (Bone marrow), placenta-derived, embryonic stem cells , iPS-derived stem cells, or skin stem cells.
  • fibroblasts which are cells that have confirmed binding to extracellular vesicles, include both negatively charged human and non-human animal-derived cells.
  • the present invention also relates to a cosmetic composition
  • a cosmetic composition comprising the conditioned culture medium and a cosmetically acceptable additive or carrier.
  • the cosmetic composition may have a use for strengthening skin regeneration or strengthening skin barrier.
  • the cosmetic composition may include components commonly used in the cosmetic composition as well as the conditioned culture solution of the present invention, for example, antioxidants, stabilizers, solubilizers, vitamins, customary adjuvants such as pigments and fragrances, and carriers.
  • the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, surfactant-containing cleansing oil, emulsion It may be formulated as a foundation, a wax foundation, and a spray, but is not limited thereto. More specifically, lotion, nourishing lotion, nourishing cream, moisture cream, massage cream, eye cream, essence, paste, mask pack, patch, gel, cream, lotion, powder, soap, cleanser, oil, foundation, makeup base, It can be prepared in the form of a wax or spray.
  • a solution, suspension, emulsion, paste, gel, cream, lotion, surfactant-containing cleansing oil, emulsion It may be formulated as a foundation, a wax foundation, and a spray, but is not limited thereto. More specifically, lotion, nourishing lotion, nourishing cream, moisture cream, massage cream, eye cream, essence, paste, mask pack, patch, gel, cream, lotion, powder, soap, cleanser, oil, foundation,
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the conditioned culture medium and a pharmaceutically acceptable additive or carrier.
  • the pharmaceutical composition may have a use for strengthening skin regeneration or strengthening the skin barrier.
  • the pharmaceutical composition of the present invention may be formulated using a pharmaceutically acceptable additive, carrier and/or excipient according to a method that can be easily performed by a person of ordinary skill in the art to which the present invention pertains.
  • the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may additionally contain a dispersant or stabilizer.
  • the pharmaceutical composition may be formulated for external use for the skin, and more specifically, may be prepared in the form of ointments, creams, gels, sprays, skin patches, dressings, masks, non-adhesive gauze, and the like.
  • the pharmaceutical composition may be formulated as an injection, and more specifically, may be prepared in the form of subcutaneous injection, intradermal injection, and the like.
  • the pharmaceutical composition may be prepared for administration to a mammal, more preferably for administration to a human.
  • Pharmaceutically acceptable carriers may be solid or liquid, and include excipients, antioxidants, buffers, bacteriostats, dispersants, adsorbents, surfactants, binders, preservatives, disintegrants, sweeteners, flavoring agents, lubricants, release controlling agents, wetting agents, It may be at least one selected from a stabilizer, a suspending agent, and a lubricant.
  • the pharmaceutically acceptable carrier may be selected from saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures thereof.
  • the pharmaceutical composition may be formulated for external use for skin. In another embodiment, the pharmaceutical composition may be formulated for subcutaneous injection or intradermal injection.
  • the method of separating extracellular vesicles used herein is a method of separating other extracellular vesicles, for example, ultracentrifuge, density gradient, ultracentrifugation. It may be filtration (Ultrafiltration), immunoaffinity purification (Immunoaffinity purification), but is not limited to the method specified above (Mol Ther Nucleic Acids. 2018 Mar 2;10:131-141).
  • skin regeneration refers to a skin regeneration effect of the dermal layer of the skin, and an increase in the proliferation rate of dermal fibroblasts in the dermal layer and an increase in extracellular matrix synthesis comprehensively. However, based on the results from the human tissue model, it may be the effect of the epidermal layer rather than the dermal layer alone.
  • NF-CM Nutrient Full media-Conditioned medium
  • NFL-CM Nutrient Full media with Lactoferrin-Conditioned medium
  • extracellular vesicles isolated from NF-CM are expressed as “NF-EVs (NF-Extracellular vesicles)”
  • extracellular vesicles isolated from NFL-CM are expressed as “NFL-EVs (NFL-Extracellular vesicles)”.
  • the present inventors found that the lactoferrin added to the culture medium binds to the increased extracellular vesicles in the culture medium, and this binding reduces the negative charge of the extracellular vesicles and increases the binding ability with the cells. Confirmed.
  • the present inventors confirmed that the conditioned culture medium containing a high concentration of extracellular vesicles bound to lactoferrin enhances the regeneration efficacy of skin fibroblasts by increasing the proliferation rate of skin fibroblasts and increasing the expression of extracellular matrix.
  • the present inventors have demonstrated that the skin regeneration enhancing effect of the conditioned medium is due to the quantitative and qualitative change of extracellular vesicles in the culture medium.
  • the present inventors confirmed that the extracellular vesicles in the conditioned culture medium showed increased skin tissue permeability and increased the amount of extracellular matrix secreted by the skin tissue using a skin tissue model.
  • the present inventors confirmed the effect of maintaining the skin barrier and increasing skin barrier recovery of the conditioned culture medium.
  • Example 1 Confirmation of extracellular vesicles derived from adipose-derived stem cell culture medium
  • Human adipose-derived mesenchymal stem cells were cultured for 72 hours in a 175 cm 2 cell culture dish (T175 flask). After 72 hours, it was washed with a phosphate buffer solution, and an additive-free medium (Alpha-Minimum Essential Medium, alpha-MEM) was added and incubated for 24 hours. Thereafter, calcium (CaCl 2 , sigma, USA) and lactoferrin (Lactoferrin, aspira scientific, USA) were mixed in a medium containing serum replacement and the cells were treated. In addition, the group containing only serum replacement was also conducted. After 48 hours, the culture solution was collected and filtered through a 0.22- ⁇ m filter to obtain a final culture solution.
  • the culture medium obtained after cell culture with lactoferrin/calcium composition/serum substitute was expressed as Nutrient Full media with Lactoferrin-Conditioned medium (NFL-CM), and the culture medium obtained after cell culture with only serum substitute was NF-CM (Nutrient Full media-Conditioned medium). medium) was expressed.
  • a size-based column (Size Exclusion Columns, IZONscience, New Zealand) was used.
  • the size-based column separates particles with a size of 35 - 400 nm or more, and removes small proteins not associated with exosomes in the culture medium.
  • Extracellular vesicles isolated from NF-CM were expressed as NF-EVs
  • extracellular vesicles isolated from NFL-CM were expressed as NFL-EVs.
  • the number and size of extracellular vesicles in NF-EVs and NFL-EVs were measured with a nanoparticle tracking analysis (Nanoparticle tracking analysis, NTA, Nanosight NS300, Malvern, UK). A graph of is shown in FIG. 2 .
  • Negative staining was performed to observe the shape of the isolated extracellular vesicles.
  • the separated extracellular vesicles are washed with a washing solution in the exosome staining kit (Exosome-TEM-easy kit, 101bio, USA). Thereafter, negative staining was performed with uranyl acetate in the kit for 10 minutes, dried at room temperature, and observed at 120 kV with a transmission electron microscope (Transmission Electron Microscope, TEM, Talos L120c, FEI, Czech).
  • both NF-EVs and NFL-EVs could be observed to be surrounded by the shape of a lipid bilayer, and it was observed that they had a cup shape, which is the shape of a conventional extracellular vesicle.
  • the lactoferrin/calcium composition increases the number of extracellular vesicles in the culture medium, but does not affect the size or shape of the extracellular vesicles.
  • Example 2 Confirmation of increased binding ability with skin cells by binding of lactoferrin to extracellular vesicles produced by the lactoferrin/calcium composition
  • the experiment was carried out thinking that the lactoferrin added to the culture medium would bind to the increased extracellular vesicles in the culture medium and increase the binding ability with skin cells.
  • Example 2 extracellular vesicles isolated from the culture medium were reacted with lactoferrin-gold antibody and observed with a transmission electron microscope.
  • extracellular vesicles were fixed (4% paraformaldehyde), blocked (0.4% bovine serum albumin), lactoferrin antibody reaction, and finally negative staining was performed with uranyl acetate. After drying at room temperature, it was observed with a transmission electron microscope at 120 kV, and is shown in FIG. 4 .
  • Extracellular vesicles isolated from the culture medium obtained after cell culture with lactoferrin/calcium composition/serum substitute were expressed as NFL-EVs
  • extracellular vesicles isolated from the culture medium obtained after cell culture with serum replacement were expressed as NF-EVs. .
  • lactoferrin bound to the extracellular vesicles was confirmed using an enzyme-linked immunosorbent assay (ELISA), and the method is as follows.
  • lactoferrin and various proteins not bound to extracellular vesicles in the culture medium were removed with a size-based column, and the number of separated extracellular vesicles was measured by the method of nanoparticle tracking analysis (NTA). . Based on the measured number, the amount of lactoferrin bound to 2 ⁇ 10 9 NF-EVs and NFL-EVs was measured using a Lactoferrin ELISA kit (NOVUS, USA).
  • the quantitative substance of the lactoferrin ELISA kit and the extracellular vesicles were put into a 96-well plate coated thereto, and then reacted at 37° C. for 2 hours. After that, the first antibody (Detection antibody) was attached and the second antibody (HRP antibody) was attached, and washing was performed at least 3 times with a phosphate buffer solution between each process. Finally, a substrate and a stop buffer were put, and absorbance was measured at 450 nm with an ELISA reader (Molecular devices, USA), and the quantitative value is shown in FIG. 5 .
  • lactoferrin bound to 2 ⁇ 10 9 NFL-EVs was 135 ng/ml, while the amount of lactoferrin bound to 2 ⁇ 10 9 NF-EVs was 4.5 ng/ml. It was found that lactoferrin bound to NFL-EVs was 30 times that of lactoferrin bound to NF-EVs. expected to induce functional enhancement (unpaired T-test, ***;p ⁇ 0.0001).
  • the negative charge of NFL-EVs cultured in a culture medium containing lactoferrin was significantly weaker than that of NF-EVs.
  • NF-EVs confirmed a charge of -60 ⁇ 64 mV, but in the case of NFL-EVs, a charge of -20 ⁇ 30 mV was confirmed, so that when lactoferrin was incubated with lactoferrin, extracellular vesicles were combined with positive lactoferrin to reduce the negative charge. It was found to be consistent with one result (unpaired T-test, **;p ⁇ 0.001).
  • the decrease in the negative charge of the extracellular vesicles was expected to show an increase in the binding of NFL-EVs to the cell membrane, and the experiment was carried out.
  • the difference in binding ability between NFL-EVs and NF-EVs with human dermal fibroblasts was confirmed by fluorescence activated cell sorting (FACS, ACEA, USA).
  • the extracellular vesicles were separated by a size-based column as in Example 1.
  • the stained extracellular vesicles were treated with 5 ⁇ 10 6 fibroblasts per group for 3 hours, washed with phosphate buffer solution, and cells were washed with 1 ⁇ trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA, welgene, Korea) solution. It was isolated from the culture dish.
  • the cells were washed and diluted with a phosphate buffer solution, and the green fibroblasts binding to the extracellular vesicles were confirmed by fluorescence-activated cell isolation.
  • Fibroblasts present in the dermal layer of the skin are a major source of proteins of the extracellular matrix of the dermal layer, such as collagen, piperonectin, and elastin.
  • the extracellular matrix plays a major role in maintaining skin structure and elasticity, and thus the proliferation of fibroblasts and the increase of extracellular matrix proteins play an important role in preventing skin aging (Mol Cell Biochem. 2019 Oct 10).
  • the serum replacement culture medium containing the lactoferrin/calcium composition was expressed as Nutrient Full media with Lactoferrin-Conditioned medium (NFL-CM), and the culture medium containing only the serum replacement medium was expressed as NF-CM (Nutrient Full media-Conditioned medium).
  • a fibroblast suspension of 2 ⁇ 10 4 cells/ml was placed in a 48-well plate with 48 holes and cultured for 24 hours.
  • 250 ⁇ l of NF-CM and NFL-CM were treated, and an additive-free medium (SF) was used as a negative control.
  • SF additive-free medium
  • each medium was removed after incubation at 37° C. for 48 hours and washed three times with a phosphate buffer solution.
  • the MTT solution (0.5 mg/ml) was reacted for 2 hours and mixed, and then the absorbance was measured at 570 nm by stirring in an isopropyl alcohol solution for 30 minutes. Result values are graphed with relative values when SF is set to 100%.
  • the cell state was observed under a microscope (inverted microscope, Olympus corporation, Japan) and shown in FIG. 8 together.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • RNA extraction kit TAKARA MiniBEST universal RNA extraction kit, TAKARA, Japan.
  • Example 4 Confirmation that the increase in skin cell proliferation rate by the NFL-CM culture is due to quantitative and qualitative changes in extracellular vesicles in the culture medium
  • Example 3 an experiment was prepared to prove that the increase in the proliferation rate of fibroblasts by the culture medium produced through the lactoferrin/calcium composition is due to the extracellular vesicles present in the culture medium.
  • a filtration spin column (Vivaspin20, Sartorius, UK) of 300,000 MWCO (Molecular Weight Cut-Off), which is generally used for concentrating the culture medium, was used. After putting the culture solution in the column, the culture solution was filtered through centrifugation. filter The filtered culture solution was used as a culture solution from which extracellular vesicles were removed, and the culture solution from which extracellular vesicles were removed from NFL-CM in FIG. 10 was called “EVs-depleted NFL-CM”, and the culture solution from which extracellular vesicles had been removed from NF-CM was used. Each was expressed as "EVs-depleted NF-CM”.
  • fibroblasts were treated with the same amount of NF-CM, EVs-depleted NF-CM, NFL-CM, and EVs-depleted NFL-CM for two days. sey proceeded.
  • the method is the same as in FIG. 8 of Example 3.
  • NF-CM and EVs-depleted NF-CM did not show a significant difference in cell proliferation rate, whereas in the case of EVs-depleted NFL-CM from which extracellular vesicles were removed from NFL-CM, the proliferation rate of fibroblasts was decreased significantly (Unpaired T-test, NS; p > 0.05, ***; p ⁇ 0.0001). As a result, the reason why NFL-CM showed a large difference in fibroblast proliferation compared to NF-CM was demonstrated that NFL-EVs of NFL-CM acted as a major factor.
  • Example 5 Confirmation of increased regenerative capacity due to increased permeability of extracellular vesicles in lactoferrin/calcium composition culture medium in skin tissue model
  • fibroblasts synthesize extracellular matrix such as collagen, elastin, and fibronectin in the dermal layer, when cells are damaged, they secrete metalloprotase that breaks down collagen, a major factor in the extracellular matrix, to form the extracellular matrix.
  • metalloproteinase is regulated by thymp, an inhibitor produced by fibroblasts.
  • skin structure and elasticity are maintained through the balance of various elements created by fibroblasts, and when the balance is broken, skin aging is induced (Exp Cell Res. 2001 Dec 10;271(2):249-62) .
  • extracellular vesicles are highly permeable to the skin (BBRC, 2017, Nov 18; 493(2): 1102-1108), and furthermore, as confirmed in Example 2, extracellular vesicles in the conditioned culture medium of the present invention are Since the number of cells is large and the ability to bind to skin cells is high due to a decrease in negative charge, the conditioned culture medium was prepared for an experiment in anticipation of high skin penetration ability and regenerative effect.
  • Example 2 After staining the extracellular vesicles with a lipophilic dye, they were separated by a size-based column as in Example 1. After transferring a three-dimensional skin model (KeraSkinTM-FT, Biosolution, Korea) to a 6-well plate containing assay-media, 100 ⁇ l of each of the stained extracellular vesicles was treated. After 6 hours, the tissue was fixed (4% formaldehyde), washed, dehydration, clearing, infiltration, and embedding to make a paraffin block. The paraffin block was sectioned with a microtome (Automated microtome, Leica, Germany).
  • a microtome Automated microtome, Leica, Germany
  • the samples were later run in two ways.
  • the tissue was subjected to nuclear staining and tissue protection using a mounting solution (Mounting medium, Vector laboratories, USA) containing DAPI (DAPI, 4',6-diamidino-2-phenylindole), followed by a fluorescence microscope (DM4000B).
  • DAPI DAPI, 4',6-diamidino-2-phenylindole
  • DM4000B fluorescence microscope
  • fluorescence microscopy Leica, Germany
  • H&E Hematoxylin and eosin
  • observation was made at 400 times magnification through a tissue observation microscope (BX41, Olympus, Japan), and images were taken at the same magnification.
  • NFL-EVs showed excellent tissue permeability. Although it showed a lot of NFL-EVs in the epidermis, it was confirmed that the NFL-EVs penetrated inside and accumulated in the dermis.
  • Filaggrin affects the physical support of the skin barrier by linking keratin with each other in the outermost layer of the skin that protects the human body from the outside.
  • the final product of filaggrin is a natural moisturizing factor and has the function of maintaining skin moisture, so filaggrin acts as a major factor in skin barrier and moisturizing.
  • filaggrin fluorescence staining was performed.
  • the culture medium obtained after cell culture with lactoferrin/calcium composition/serum substitute was expressed as Nutrient Full media with Lactoferrin-Conditioned medium (NFL-CM).
  • a cover slip of 12 ⁇ into the hole put a cover slip of 12 ⁇ into the hole, and then put 500 ⁇ l of a 2 ⁇ 10 4 cells/ml keratinocyte (HaCaT) suspension. Incubated for 48 hours. After removing the culture medium (Dulbecco's Modified Eagle Medium, DMEM, Welgene, Korea), 250 ⁇ l of the culture medium and 250 ⁇ l of NFL-CM were treated, and an additive-free medium was used as a negative control. After inoculation, each medium was removed and stained with filaggrin after incubation for 5 days at 37°C.
  • DMEM Dulbecco's Modified Eagle Medium
  • Fixative 2% formaldehyde, sigma, USA
  • permeabilization (0.2% Triton-X 100, MP biomedical, Germany
  • Blocking 5% fetal bovine serum
  • antibody reaction Filaggrin antibody, Thermofisher, USA
  • second antibody reaction Fluorescein horse anti-mouse IgG antibodies, vector laboratories, USA
  • nuclear staining and cell protection were performed using a mounting solution (Mounting medium, Vector laboratories, USA). The results were confirmed with a fluorescence microscope (DM4000B, fluorescence microscopy, Leica, Germany).
  • filaggrin immunostaining In order to confirm the effect of the culture medium prepared in Example 1 on filaggrin in skin tissue, filaggrin immunostaining (Immunohistochemistry) was performed. Specifically, a 3D human skin epidermal model (KeraSkinTM, Biosolution, Korea) was treated with 10% sodium dodecyl sulfate (SDS, Sodium Dodecyl Sulfate) to break the cell barrier, and then treated with NFL-CM. After 4 days, the tissues were fixed in a fixative solution (4% formaldehyde, sigma, USA) for 4 hours and washed with running water for 4 hours to remove the fixative solution.
  • a fixative solution 4% formaldehyde, sigma, USA
  • Example 5 dehydration, clearing, infiltration, embedding, thinning, drying, deparaffinization, hydration, permeation (0.2% Triton-X) 100), and then washed 3 times with a phosphate buffer solution.
  • the antigen was exposed with 0.01M sodium citrate. Thereafter, blocking, Filaggrin antibody reaction (Filaggrin antibody, Thermofisher, USA), and biotinylated secondary antibody [biotinylated universal (Anti-Mouse IgG/Rabbit IgG) antibody] were reacted. Each process included a washing process.
  • filaggrin was stained brown.
  • sodium dodecyl sulfate was treated alone, it was confirmed that the skin epidermal tissue was damaged, and the amount of filaggrin was also small.
  • the damaged epidermal tissue was recovered as much as the existing skin tissue, and it was observed that the amount of filaggrin was also increased.
  • NFL-CM has the effect of restoring the damaged skin barrier by increasing filaggrin, which is a major factor in skin barrier and moisturizing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un milieu conditionné comprenant une concentration élevée de vésicules extracellulaires liées à la lactoferrine obtenue par culture de cellules dans un milieu de culture comprenant de la lactoferrine. De plus, la présente invention concerne une composition cosmétique et une composition pharmaceutique comprenant le milieu conditionné. De plus, la présente invention concerne une composition cosmétique et une composition pharmaceutique comprenant le milieu conditionné.
PCT/KR2020/014092 2020-01-02 2020-10-15 Milieu conditionné comprenant une concentration élevée de vésicules extracellulaires liées à la lactoferrine WO2021137398A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0000481 2020-01-02
KR1020200000481A KR102250401B1 (ko) 2020-01-02 2020-01-02 락토페린과 결합하고 있는 고농도의 세포외 소포를 함유하는 조건화 배양액

Publications (1)

Publication Number Publication Date
WO2021137398A1 true WO2021137398A1 (fr) 2021-07-08

Family

ID=75914650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/014092 WO2021137398A1 (fr) 2020-01-02 2020-10-15 Milieu conditionné comprenant une concentration élevée de vésicules extracellulaires liées à la lactoferrine

Country Status (2)

Country Link
KR (1) KR102250401B1 (fr)
WO (1) WO2021137398A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109367A1 (fr) * 2005-04-05 2006-10-19 Obihiro University Of Agriculture And Veterinary Medicine Méthode de libération cellulaire, solution de libération cellulaire, méthode de culture cellulaire, milieu de culture cellulaire, solution cellulaire, préparation de solution cellulaire, méthode de colonisation cellulaire et solution de colonisation cellulaire
US20090130191A1 (en) * 2005-10-27 2009-05-21 Sunstar Inc. Osteoclast Growth Inhibitor, Oral Composition, and Preventive or Therapeutic Agent for Bone Diseases, Containing Liposome-Encapsulated Lactoferrin
KR102132457B1 (ko) * 2019-05-10 2020-07-09 주식회사 바이오솔루션 세포외 소포를 고농도로 배양하기 위한 세포 배양배지 및 상기 세포 배양배지를 이용한 세포외 소포 고 함유 조건화 배양액의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109367A1 (fr) * 2005-04-05 2006-10-19 Obihiro University Of Agriculture And Veterinary Medicine Méthode de libération cellulaire, solution de libération cellulaire, méthode de culture cellulaire, milieu de culture cellulaire, solution cellulaire, préparation de solution cellulaire, méthode de colonisation cellulaire et solution de colonisation cellulaire
US20090130191A1 (en) * 2005-10-27 2009-05-21 Sunstar Inc. Osteoclast Growth Inhibitor, Oral Composition, and Preventive or Therapeutic Agent for Bone Diseases, Containing Liposome-Encapsulated Lactoferrin
KR102132457B1 (ko) * 2019-05-10 2020-07-09 주식회사 바이오솔루션 세포외 소포를 고농도로 배양하기 위한 세포 배양배지 및 상기 세포 배양배지를 이용한 세포외 소포 고 함유 조건화 배양액의 제조방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARK SOON YONG, JEONG AE-JIN, KIM GEUN-YOUNG, JO ARA, LEE JOO EON, LEEM SUN-HEE, YOON JOUNG-HAHN, YE SANG KYU, CHUNG JIN WOONG: "Lactoferrin Protects Human Mesenchymal Stem Cells from Oxidative Stress-Induced Senescence and Apoptosis", JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, KOREAN SOCIETY FOR APPLIED MICROBIOLOGY , SEOUL, KR, vol. 27, no. 10, 28 October 2017 (2017-10-28), KR, pages 1877 - 1884, XP055825102, ISSN: 1017-7825, DOI: 10.4014/jmb.1707.07040 *
PATRAS KATHRYN A., HA ALBERT D., ROOHOLFADA EMMA, OLSON JOSHUA, RAMACHANDRA RAO SATISH P., LIN ANN E., NIZET VICTOR: "Augmentation of Urinary Lactoferrin Enhances Host Innate Immune Clearance of Uropathogenic Escherichia coli", JOURNAL OF INNATE IMMUNITY, S. KARGER AG, CH, vol. 11, no. 6, 1 January 2019 (2019-01-01), CH, pages 481 - 495, XP055825103, ISSN: 1662-811X, DOI: 10.1159/000499342 *
SOMIYA MASAHARU, YOSHIOKA YUSUKE, OCHIYA TAKAHIRO: "Biocompatibility of highly purified bovine milk‐derived extracellular vesicles", JOURNAL OF EXTRACELLULAR VESICLES, TAYLOR & FRANCIS, UK, vol. 7, no. 1, 1 December 2018 (2018-12-01), UK, pages 1440132, XP055825099, ISSN: 2001-3078, DOI: 10.1080/20013078.2018.1440132 *

Also Published As

Publication number Publication date
KR102250401B1 (ko) 2021-05-11

Similar Documents

Publication Publication Date Title
WO2017123022A1 (fr) Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
WO2020022731A1 (fr) Composition cosmétique comprenant un exosome dérivé de cellules souches de rose en tant que principe actif
WO2019004757A9 (fr) Utilisation d'une composition comprenant un exosome dérivé de cellules souches à titre de principe actif pour la prévention ou le soulagement du prurit
WO2020071662A1 (fr) Composition comprenant des exosomes induits destinée à la régénération des cheveux
KR102403851B1 (ko) 모유두전구세포로부터 분리된 엑소좀 및 이의 용도
KR101422559B1 (ko) 지방유래 줄기세포 배양액, 이의 제조방법, 및 이를 포함하는 발모촉진용 조성물
WO2021020726A1 (fr) Nouveau procédé de production d'exosomes et son application
WO2021201637A1 (fr) Procédé de préparation d'un milieu de culture contenant des niveaux élevés d'exosomes hautement puissants sécrétés par des cellules souches de sang de cordon ombilical et utilisation correspondante
WO2010079978A2 (fr) Composition utilisable pour le traitement de l'inflammation faisant appel à des antigènes abh
WO2021241798A1 (fr) Méthode de préparation d'un exosome dérivé d'une cellule souche mésenchymateuse et culture cellulaire préparée à partir dudit exosome
WO2022177217A2 (fr) Composition pour la régénération, le blanchiment, l'antioxydation de la peau, ou le traitement des plaies, comprenant un exosome dérivé de cellules souches utilisé en tant que principe actif, et utilisation associée
WO2013180526A1 (fr) Activateur de régénération cutanée et de croissance capillaire contenant un extrait d'edelweiss
WO2023120900A1 (fr) Composition cosmétique pour réduire la chute des cheveux ou favoriser la pousse des cheveux comprenant un promoteur de croissance cellulaire en tant que principe actif
WO2011136434A1 (fr) Concentré de culture liquide de cellules souches dérivées d'un tissu adipeux humain ayant un effet de régénération de la peau ou d'atténuation des rides, et son utilisation
WO2021137398A1 (fr) Milieu conditionné comprenant une concentration élevée de vésicules extracellulaires liées à la lactoferrine
KR101336474B1 (ko) 지방 유래 성체줄기세포 배양액의 나노섬유 또는 나노캡슐을 포함하는 화장료 조성물 및 그 제조방법
WO2014081255A1 (fr) Composition cosmétique anti-vieillissement contenant des fractions liposolubles de venin d'abeille et procédé de préparation associé
WO2012102456A1 (fr) Composition cosmétique pour réduire les rides contenant des extraits d'euphorbia supina
JP2021001166A (ja) 神経幹細胞培養液を有効成分として含む皮膚改善用組成物
WO2019112238A2 (fr) Composition cosmétique pour hydrater la peau comprenant un exosome dérivé de cellules souches en tant qu'ingrédient actif
WO2021096089A1 (fr) Nouvelle composition comprenant des exosomes dérivés de cellules souches et du polydésoxyribonucléotide en tant que principes actifs
WO2022240243A1 (fr) Composition de blanchiment de la peau contenant des nanovésicules
WO2021246559A1 (fr) Exosomes séparés de cellules précurseurs de papille dermique et leur utilisation
WO2021182725A1 (fr) Utilisation de milieu conditionné pour soulager et prévenir la perte de cheveux contenant une concentration élevée de vésicules extracellulaires ayant une fonction améliorée
WO2023048339A1 (fr) Composition comprenant un réticulum endoplasmique dérivé de cellules souches d'amygdale humaine en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20910657

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20910657

Country of ref document: EP

Kind code of ref document: A1